SpringerLink
Log in

CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis

  • Research Article
  • Published:
Tumor Biology

Abstract

CIP2A is a recently characterized oncoprotein which involves in the progression of several human malignancies. This study aimed to investigate its clinical significance and biological function in ovarian cancer. CIP2A expression was analyzed in 152 archived ovarian cancer specimens using immunohistochemistry. One hundred cases (65.79 %) showed CIP2A overexpression, including 63 of 92 serous carcinomas (68.48 %), 21 of 33 endometrioid carcinomas (63.64 %), 12 of 23 mucinous carcinomas (52.17 %), and 4 of 4 clear cell carcinomas (100 %). There is no significant difference of CIP2A expression between serous tumors and all other morphologies combined. CIP2A overexpression positively correlated with advanced FIGO stage (p = 0.0336) and tumor grade (p = 0.0213). siRNA knockdown was performed in A2780 and SKOV3 cell lines. MTT, colony formation assay, and flow cytometry were carried out to assess the role of CIP2A in proliferation, cell cycle, and apoptosis. CIP2A depletion in ovarian cancer cell lines inhibited proliferation, blocked cell cycle progression, and increased paclitaxel-induced apoptosis. Futhermore, CIP2A depletion downregulated cyclin D1, c-myc, phospho-Rb, Bcl-2, and phospho-AKT expression. These results validate the role of CIP2A as a clinically relevant oncoprotein and establish CIP2A as a promising therapeutic target of ovarian cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Thailand)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60(5):277–300.

    Article  PubMed  Google Scholar 

  2. Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol. 2009;472:413–37.

    Article  PubMed  Google Scholar 

  3. Darcy KM and Birrer MJ. 2010.Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies. Gynecol Oncol. 117(3): p. 429–39.

    Google Scholar 

  4. Despierre E, Lambrechts D, Neven P, Amant F, Lambrechts S and Vergote I. 2010. The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. Gynecol Oncol. 117(2): p. 358-65

    Google Scholar 

  5. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130(1):51–62.

    Article  PubMed  CAS  Google Scholar 

  6. Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW and Chen KF. 2012. CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res. 14(2): p. R68.

    Google Scholar 

  7. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, et al. 2010. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene. 29(47): p. 6257-66.

    Google Scholar 

  8. Lin YC, Chen KC, Chen CC, Cheng AL and Chen KF. 2012. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. Oral Oncol 48(7):585-93

    Google Scholar 

  9. Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res. 2009;15(16):5092–100.

    Article  PubMed  CAS  Google Scholar 

  10. Niemela M, Kauko O, Sihto H, Mpindi JP, Nicorici D, Pernila P, et al. 2012. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene (in press)

  11. Li W, Ge Z, Liu C, Liu Z, Bjorkholm M, Jia J, et al. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res. 2008;14(12):3722–8.

    Article  PubMed  CAS  Google Scholar 

  12. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ, et al. 2011. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol. 18(3): p. 857-65.

    Google Scholar 

  13. Vaarala MH, Vaisanen MR and Ristimaki A. 2010. CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res. 29: p. 136.

    Google Scholar 

  14. Bockelman C, Koskensalo S, Hagstrom J, Lundin M, Ristimaki A and Haglund C. 2012. CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer Biol Ther. 13(5):289–95.

    Google Scholar 

  15. Ren J, Li W, Yan L, Jiao W, Tian S, Li D, et al. 2011. Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients' survival. Br J Cancer. 105(12): p. 1905-11.

    Google Scholar 

  16. Bockelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, Haglund C, et al. 2011. Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer. 105(7): p. 989-95.

    Google Scholar 

  17. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 2002;62(16):4722–9.

    PubMed  CAS  Google Scholar 

  18. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005;11(18):6422–30.

    Article  PubMed  CAS  Google Scholar 

  19. Kim A, Ueda Y, Naka T and Enomoto T. 2012. Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res. 31: p. 14.

    Google Scholar 

  20. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol. 2008;26(32):5284–93.

    Article  PubMed  Google Scholar 

  21. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 2006;25(11):1620–8.

    Article  PubMed  CAS  Google Scholar 

  22. Roy PG, Thompson AM. Cyclin D1 and breast cancer. Breast. 2006;15(6):718–27.

    Article  PubMed  Google Scholar 

  23. Ratschiller D, Heighway J, Gugger M, Kappeler A, Pirnia F, Schmid RA, et al. Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol. 2003;21(11):2085–93.

    Article  PubMed  CAS  Google Scholar 

  24. Keum JS, Kong G, Yang SC, Shin DH, Park SS, Lee JH, et al. Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer. Br J Cancer. 1999;81(1):127–32.

    Article  PubMed  CAS  Google Scholar 

  25. Bali A, O'Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res. 2004;10(15):5168–77.

    Article  PubMed  CAS  Google Scholar 

  26. Masamha CP, Benbrook DM. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res. 2009;69(16):6565–72.

    Article  PubMed  CAS  Google Scholar 

  27. Mateyak MK, Obaya AJ, Sedivy JM. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol. 1999;19(7):4672–83.

    PubMed  CAS  Google Scholar 

  28. Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE, et al. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem. 2000;275(15):10761–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This work was supported by grants from the National Natural Science Foundation of China (No. 30973191).

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Gynecology and Obstetrics, Sheng**g Hospital of China Medical University, 36 Sanhao Street, 110004, Shenyang, People’s Republic of China

    Yuanyuan Fang, Zhengtao Li, **uxia Wang & Shulan Zhang

Authors
  1. Yuanyuan Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhengtao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. **uxia Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shulan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shulan Zhang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fang, Y., Li, Z., Wang, X. et al. CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis. Tumor Biol. 33, 2299–2306 (2012). https://doi.org/10.1007/s13277-012-0492-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-012-0492-2

Keywords

Search

Navigation